Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study

BackgroundPatients with advanced intrahepatic cholangiocarcinoma (iCCA) have a poor prognosis and a substantial unmet clinical need. The study was aimed to investigate the efficacy and safety of sintilimab combined with lenvatinib for advanced iCCA in second-line setting.MethodsThe patients at multi...

Full description

Bibliographic Details
Main Authors: Xiaoyan Ding, Guangxin Li, Wei Sun, Yanjun Shen, Ying Teng, Yawen Xu, Wendong Li, Mei Liu, Jinglong Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
intrahepatic cholangiocarcinoma
sintilimab
lenvatinib
second-line treatment
PD-L1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.907055/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.907055/full

Similar Items